Skip to content
thestock.space

BALAXI PHARMACEUTICALS (BALAXI) had a P/E of 48.8× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 49% below their 52-week high. Sales and net profit fell 7.0% and 69% a year over 3 years; its ROCE of 3.3% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.23× equity. It is a small-cap company with a market cap of ₹121 Cr, ranked 114th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 49% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹22.40
Day high
₹22.40
Day low
₹21.30
Prev. close
₹21.89
Volume
12.9K

Health check

1 fair · 5 to check
  • ReturnsBehind

    −48.8% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 48.8 vs industry 28.7.

  • GrowthShrinking

    Sales −7.0%, profit −68.6% a year over 3 years.

  • ProfitabilityWeak

    ROCE 3.3% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.23× equity, interest covered 2.4×, Piotroski 4 of 9.

  • Red flags4 to check

    Return on equity is low at 0.6%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹121 Cr, #114 of 154 in its industry by size.

Defensive

Beta 0.74 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹280 Cr · profit ₹2 Cr
Market cap
₹121 Cr
Small cap
P/E
48.8
Industry 28.7
Price to book
0.49
Peers 4.99
Dividend yield
0.00%
ROE
0.6%
Peers 14.7%
ROCE
3.3%
Peers 17.9%
Debt to equity
0.23
Debt ₹58 Cr
EPS (TTM)
₹0.45
Face value ₹2
OPM (TTM)
2.9%
Net margin 0.9%
Sales growth
+14.1%
Latest quarter vs a year ago
Profit growth
+347.2%
Latest quarter vs a year ago
Price to sales
0.43
EV/EBITDA 19.4

Strengths and risks

Strengths

  • Quarterly profit up 347.2% on a year ago.

Risks to check

  • Return on equity is low at 0.6%.
  • P/E of 48.8 against an industry P/E of 28.7.
  • 49% below its 52-week high.
  • Interest coverage of only 2.5×.

Derived automatically from reported figures. Not a recommendation.

About BALAXI PHARMACEUTICALS

Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceutical products in India and internationally. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The…

Headquarters
Hyderabad
Employees
500
Sector
Healthcare
ISIN
INE618N01022
Website
balaxipharma.in

Price range

52 weeks

₹15.20₹42.74

Today

₹21.30₹22.40
Avg volume (3M)
36.1K
1-year return
minus 48.8%
From 52-week high
minus 48.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
BALAXIBALAXI PHARMACEUTICALS21.96plus 0.32%12148.80.493.3%0.6%3.2%−7.0%−68.6%0.00%minus 48.8%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
70.756.272.570.780.7
68.45569.570.677
2.41.23.10.13.7
3.4%2.1%4.3%0.2%4.5%
01.60.12.90
10.9110.7
0.50.50.60.60.8
0.91.41.61.42.1
67.9%84.8%81.1%56.3%37.9%
0.30.20.30.61.3
0.050.040.060.110.24

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−7.0%
Profit CAGR 3Y
−68.6%
EPS CAGR 3Y
−69.4%
ROE
0.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
336241293270
–minus 28.3%+21.2%minus 7.7%
279236254261
57.45.838.39.6
17.1%2.4%13.1%3.6%
1.838.4−4.81.8
0.51.72.93.9
1.82.11.92.2
–−38.4–−0.1
56.9228.75.3
19.3%218.4%12.6%73.2%
46−2.425.11.4
–minus 105.2%–minus 94.3%
9.08-2.324.540.26

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.210.91111
173190221238
13.319.453.457.6
43.537.625.230.3
240258310337
18.116.335.748.4
2.82.322.1–
––0.1–
28.262.339.414.6
191177213274
240258310337

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6.14.9−35−4.5
−10.6−1−21.8−20.8
25.530.333.90.4
2134.1−22.9−24.8
−15−1.6−21.8−42.9
−8.93.3−56.8−47.4
−0.5–––

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you